5CV Stock Overview
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
CureVac N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.38 |
52 Week High | US$11.20 |
52 Week Low | US$2.06 |
Beta | 2.5 |
1 Month Change | -16.56% |
3 Month Change | -27.94% |
1 Year Change | -61.27% |
3 Year Change | -97.41% |
5 Year Change | n/a |
Change since IPO | -94.24% |
Recent News & Updates
Recent updates
Shareholder Returns
5CV | DE Biotechs | DE Market | |
---|---|---|---|
7D | -0.9% | 1.6% | -1.4% |
1Y | -61.3% | -21.6% | 2.2% |
Return vs Industry: 5CV underperformed the German Biotechs industry which returned -23.5% over the past year.
Return vs Market: 5CV underperformed the German Market which returned 1.9% over the past year.
Price Volatility
5CV volatility | |
---|---|
5CV Average Weekly Movement | 7.8% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5CV's share price has been volatile over the past 3 months.
Volatility Over Time: 5CV's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 977 | Alexander Zehnder | www.curevac.com |
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer.
CureVac N.V. Fundamentals Summary
5CV fundamental statistics | |
---|---|
Market cap | €528.78m |
Earnings (TTM) | -€260.17m |
Revenue (TTM) | €53.76m |
9.8x
P/S Ratio-2.0x
P/E RatioIs 5CV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
5CV income statement (TTM) | |
---|---|
Revenue | €53.76m |
Cost of Revenue | €116.21m |
Gross Profit | -€62.45m |
Other Expenses | €197.71m |
Earnings | -€260.17m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.16 |
Gross Margin | -116.17% |
Net Profit Margin | -483.96% |
Debt/Equity Ratio | 0% |
How did 5CV perform over the long term?
See historical performance and comparison